Back HCV Treatment

HCV Treatment

AASLD 2014: AbbVie Next-Generation Hepatitis C Drugs Promising in Early Studies

AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in patients with genotype 1 chronic hepatitis C in a 3-day monotherapy study, as well as potent and synergistic activity against multiple HCV genotypes in laboratory replicon studies, according to presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting held recently in Boston.

alt

Read more:

AbbVie's Viekirax + Exviera "3D" Hepatitis C Regimen Approved in Europe

The European Commission last week approved AbbVie's interferon-free Viekirax plus Exviera combination regimen -- formerly known as "3D" -- for the treatment of genotype 1 chronic hepatitis C. This approval includes people with compensated liver cirrhosis, liver transplant recipients, HIV/HCV coinfected patients, and people on opioid substitution therapy for drug addiction. The commission also approved Viekirax plus ribavirin for HCV genotype 4.

alt

Read more:

Merck Plans to Discontinue Boceprevir for Hepatitis C by December 2015

Merck will stop selling its HCV protease inhibitor boceprevir (Victrelis) by December of this year, and no new patients should be started on the drug, the company announced in a recent "Dear Healthcare Professional" letter. While the first-generation HCV protease inhibitors improved the effectiveness of pegylated interferon plus ribavirin, they are no match in terms of efficacy or tolerability for the newer interferon-free combinations approved over the past 2 years.

alt

Read more:

Sofosbuvir/Ledipasvir + Third Drug Cures Most HCV Patients in 6 Weeks

A short and well-tolerated regimen of sofosbuvir, ledipasvir, and a third drug -- either GS-9669 or GS-9451 -- taken for as little as 6 weeks can cure a majority of previously untreated people with genotype 1 chronic hepatitis C, including those with traditional predictors of poor response, according to study results published in the January 12 advance edition of The Lancet.

alt

Read more:

2. Harvoni and Viekira Pak: Effective Oral Combinations for HCV Genotype 1

2014 saw the long-awaited U.S. Food and Drug Administration (FDA) approval of new interferon-free combination regimens for people with genotype 1 chronic hepatitis C: Gilead Sciences sofosbuvir/ledipasvir coformulation (Harvoni) in October and AbbVie's paritaprevir/ritonavir/ombitasvir plus dasabuvir regimen (Viekira Pak, formerly known as "3D") in late December. 

alt

Read more: